Working... Menu
Trial record 42 of 836 for:    Advanced | Neuroendocrine Tumors

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03017690
Recruitment Status : Completed
First Posted : January 11, 2017
Last Update Posted : December 21, 2018
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 30, 2018
  Actual Study Completion Date : May 30, 2018